Susan D Broz

Title: Susan D. Broz: Innovator in Hematopoietic Cell Therapy

Introduction

Susan D. Broz is a prominent inventor based in San Bruno, California. She has made significant contributions to the field of biomedical research, particularly in the development of therapeutic antibodies. Her work focuses on enhancing the treatment of conditions that affect blood cell production.

Latest Patents

Susan D. Broz holds a patent for "Agonist antibodies against the flk2/flt3 receptor and uses thereof." This patent describes agonist antibodies that bind to the extracellular domain of the flk2/flt3 receptor, activating its intracellular kinase domain. The labeled antibodies are valuable as diagnostics for detecting the presence of the flk2/flt3 receptor in primitive hematopoietic cells. These antibodies can stimulate the proliferation and differentiation of primitive hematopoietic cells, aiding in the repopulation of mature blood cell lineages in mammals that have undergone chemotherapy, radiation therapy, or bone marrow transplantation. Additionally, these antibodies are beneficial for treating mammals that have experienced a decrease in blood cells due to disease or hemorrhage.

Career Highlights

Susan D. Broz is associated with Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. Her work at Genentech has positioned her as a key figure in advancing therapeutic options for patients with hematological conditions.

Collaborations

Some of her notable coworkers include Brian Drake Bennett and William Matthews. Their collaborative efforts contribute to the ongoing research and development of groundbreaking therapies in the field.

Conclusion

Susan D. Broz's innovative work in the development of agonist antibodies represents a significant advancement in the treatment of blood cell-related conditions. Her contributions continue to impact the field of biomedical research positively.